Join our daily newsletter At The Bell to receive exclusive market insights
Greetings and welcome to our regular HotCopper Highlights, wrapping up Week 10, I’m Isaac McIntyre, and in this segment, we look at the stocks and company announcements you were watching this week on Australia’s #1 finance website. Let’s get straight into it, starting with the most viewed.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Investigator Silver (ASX:IVR) was far and away the most watched and discussed stock (which is why I only touch on two top-talked stocks later), as excitement continues to build around its Paris Silver deposit in South Australia.
The big billing here – from Investigator’s releases, of course – is that the explorer has “Australia’s only pure silver asset,” which many liked as the metal continues to chug along. Here are the numbers: Under the spot price case (US$80/oz silver), the project delivered a pre-Tax NPV (8%): A$1.15B, an IRR of 93%. The payback is forecast to be ~11mths from first production, the AISC was A$39.70/oz.
Then, a little later in the week, Investigator started a $55 million placement to “accelerate Paris into early works,” which probably helped the hype, too.
Next up was St George Mining (ASX:SGQ), which is working in critical minerals and has been developing the Araxá project over in Brazil recently.
St George had a funny ol’ week, where it finally shared a long-awaited resource upgrade for the expanding project, and was greeted with a brutal -20% drop through Week 10, even accounting for Thursday’s slight recovery. Some were left scratching their head considering the actual numbers weren’t too bad: Resources now stand at 70.91Mt, grading 4.06% total rare earth oxides and 0.62% niobium.
Might simply be a case of buy the hype, then sell the news, and don’t stick around to find out exactly what the news may mean. Either way, SGQ is still up some +609% in value through the last 12 months, overall.
And then, Lindian Resources (ASX:LIN) rounded out the week’s most-watched after buying a refinery in Kazakhstan for a bargain price of $US15 million.
Now, for the most discussed, where Nyrada Inc (ASX:NYR) led the way, mostly thanks to its growing clinical momentum and how far-flung the validation for its lead candidate, Xolatryp, has been recently.
During H1FY26, the company completed its Phase One clinical trial of Xolatryp and confirmed a strong safety profile and predictable pharmacokinetics in humans. No serious adverse events were reported, and observed effects were “mild to moderate and occurred across both treatment and placebo groups.”
(NYR has also been booming over +439% since this time last year, value-wise, so some HotCopper forum users may just be excited about the bags.)
Finally, American Tungsten and Antimony (ASX:AT4) roared up the listings after the company announced, via its U.S.-facing website, that reps will be meeting up with Trump Jr. quite soon. AT4’s chair, Timothy Morrison, is invited to the Hall Chadwick U.S. Capital Access Forum, and will use that platform to brief Trump Jr. on the company’s war metal project towards enriching the U.S. supply chain.
Happy days for investors, because AT4 has now climbed +19.23% through the month and looks to be staying strongly in the green to date.
American T&A has also just halted, so we’ll see what happens there.
I’d add, too, Investigator Silver was also heavily discussed, but we’ve already covered that company, and I think I’d only be repeating myself to hit it again.
So, that’s HotCopper Highlights for Week 10 of the year. I’m Isaac McIntyre, have a great weekend, and see you bright and early Monday.
Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
